Pancreatic Cancer Clinical Trial
Official title:
Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos
The study consists in a co-clinical trial by using zebrafish embryos. Specifically, an observational prospective clinical trial on patients operated of epato-biliar-pancreatic cancers and gastro-intestinal cancers undergoing a chemotherapy treatment will be run concurrently to an animal trial on zebrafish embryos xenotransplanted with patient cancer cells in order to demonstrate that zebrafish model is able to predict the therapeutic regimen with the best efficacy for each patient.
In the last years, a new concept of personalised medicine called `Mouse Avatars' or
`co-clinical trials' has emerged. Development of mouse avatars implicates implantation of
patient tumour samples in mice for use in drug efficacy studies. This model allows conducting
preclinical trials in parallel with ongoing human phase I/II clinical trials. Murine and
patient trials are conducted concurrently, and information obtained from the murine system is
used for clinical management of the patient's tumour. The advantage of this approach is that
each patient has his/her own tumour growing in an in vivo system, thereby allowing the
identification of a personalised therapeutic approach. Such approach eliminates the cost and
toxicity associated with non-targeted chemotherapy. Unfortunately, nowadays, it is clear that
co-clinical trials using mouse avatars are not affordable because mice are expensive and
time-consuming. The study challenge is to make Avatars available for every patient and the
approach sustainable for the National Healthcare Systems. To implement this concept, the
investigators propose to replace mouse Avatars with zebrafish Avatars. Indeed, the
investigators propose to run co-clinical trials by using zebrafish embryos. Zebrafish embryos
as model for human cancer cell xenografts offer several advantages:
1. Rejection-free model. In zebrafish thymus is not working until 9 days post-fertilization
(dpf), allowing rejection-free xenografts during this period. Indeed, the use of
expensive immune-permissive strains is not required, in sharp contrast to the mouse
model.
2. Very low cost of husbanding.
3. Reduced amount of testing material. Zebrafish experiments require much less material to
assess drug efficacy.
4. Short time for the analysis of xenotransplants. The time required for a drug efficacy
study is 5 days, as opposite to several weeks or months in the mouse model.
5. Low experimental cost and simple procedures. The zebrafish produces large number of
embryos with each fecundation (hundreds). This provides statistical power to the
analysis and facilitates the collection of a large number of data.
6. Low ethical impact. Zebrafish is classified as insentient from fecundation to the time
at which embryos become capable of independent feeding (120 hours post fertilization,
hpf); therefore, during this time it does not require a license according to the
Directive 2010/63/EU.
7. Data collected in zebrafish are relevant to humans. Zebrafish genome is closely related
to that of humans. For instance, remarkable similarity in molecular signalling
processes, cellular structure, anatomy, and physiology has been observed between
zebrafish and other high-order vertebrates, including humans. This accounts for the
exponential increase in the use of zebrafish in drug discovery during the last two
decades.
Collectively, these points outline the remarkable advantages of the zebrafish Avatar over the
mouse Avatar, paving the way for a realistic and cost-sustainable implementation of the
co-clinical trials.
Specifically, the aim of the study is to perform an observational prospective clinical trial
on patients operated of epato-biliar-pancreatic cancers and gastro-intestinal cancers
undergoing a chemotherapy treatment in order to demonstrate that zebrafish Avatar is able to
predict the therapeutic regimen with the best efficacy for each patient. To this effect, 120
patients meeting the trial inclusion criteria will be enrolled over a 18 months period. In
this study, a fragment of tumor will be taken from the surgical specimen by the pathologist,
fragmented and transplanted in the yolk of 48 hpf zebrafish embryos. The effect of different
anticancer drugs and/or their combinations on the survival, proliferation and migration of
the xenotransplanted cancer cells will be evaluated by exposing the xenotransplanted embryos
to fish water modified with the drugs. The chemotherapy regimens to be tested in the
xenografted embryos are selected in agreement to the common clinical practice, i.e.:
- fluoropyrimidines, platinum compounds, irinotecan, taxans (docetaxel) in stomach &
esophageal cancers
- fluoropyrimidines, platinum compounds, irinotecan, gemcitabine, nab paclitaxel in
pancreatic/biliary cancers
- fluoropyrimidines, platinum compounds, irinotecan in colorectal cancers.
Embryos will be analysed 4, 24 and 48 hours post injection (hpi). Primary measures will
include:
- cell proliferation
- cell migration
- formation of secondary masses
- induction of neo-angiogenesis
The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy
treatment.
The comparative evaluation undertaken after closure of intake will be based on prospectively
collected data on (i) clinical outcome and (ii) chemo-sensitivity data collected in zebrafish
model.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|